Drug Profile
Research programme: peptide therapeutics - Pepscan/Tibotec
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Janssen R&D Ireland; Pepscan Therapeutics
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Ireland (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Netherlands (Parenteral)
- 22 Jun 2011 Tibotec Therapeutics is now called Janssen Therapeutics